306 related articles for article (PubMed ID: 31836702)
1. Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites.
Michonneau D; Latis E; Curis E; Dubouchet L; Ramamoorthy S; Ingram B; de Latour RP; Robin M; de Fontbrune FS; Chevret S; Rogge L; Socié G
Nat Commun; 2019 Dec; 10(1):5695. PubMed ID: 31836702
[TBL] [Abstract][Full Text] [Related]
2. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
3. The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation.
Hoseinian SA; Jafari D; Mahmoodi M; Alimoghaddam K; Ostadali M; Talebzadeh Bonakdar A; Foma AM; Yekaninejad MS; Amirzargar AA
Turk J Med Sci; 2018 Aug; 48(4):794-804. PubMed ID: 30119155
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Reprogramming-A New Era How to Prevent and Treat Graft Versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Has Begun.
Kumari R; Palaniyandi S; Hildebrandt GC
Front Pharmacol; 2020; 11():588449. PubMed ID: 33343357
[TBL] [Abstract][Full Text] [Related]
5. Decreased Soluble Human Leukocyte Antigen E Levels in Patients After Allogeneic Hematopoietic Stem Cell Transplantation Are Associated With Severe Acute and Extended Chronic Graft-versus-Host Disease and Inferior Overall Survival.
Kordelas L; Schwich E; Lindemann M; Heinemann FM; Buttkereit U; Horn PA; Beelen DW; Rebmann V
Front Immunol; 2019; 10():3027. PubMed ID: 31998310
[TBL] [Abstract][Full Text] [Related]
6. Intestinal Microbiota Can Predict Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation.
Han L; Zhang H; Chen S; Zhou L; Li Y; Zhao K; Huang F; Fan Z; Xuan L; Zhang X; Dai M; Lin Q; Jiang Z; Peng J; Jin H; Liu Q
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1944-1955. PubMed ID: 31299215
[TBL] [Abstract][Full Text] [Related]
7. Multi-omics Analysis of a Fecal Microbiota Transplantation Trial Identifies Novel Aspects of Acute GVHD Pathogenesis.
Rashidi A; Ebadi M; Rehman TU; Elhusseini H; Kazadi D; Halaweish H; Khan MH; Hoeschen A; Cao Q; Luo X; Kabage AJ; Lopez S; Ramamoorthy S; Holtan SG; Weisdorf DJ; Khoruts A; Staley C
Cancer Res Commun; 2024 Jun; 4(6):1454-1466. PubMed ID: 38767452
[TBL] [Abstract][Full Text] [Related]
8. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
9. Mismatch on glutathione S-transferase T1 increases the risk of graft-versus-host disease and mortality after allogeneic stem cell transplantation.
Martínez-Bravo MJ; Calderón-Cabrera C; Márquez-Malaver FJ; Rodríguez N; Guijarro M; Espigado I; Núñez-Roldán A; Pérez-Simón JA; Aguilera I
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1356-62. PubMed ID: 24844856
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-host disease management.
Mistrik M; Bojtarova E; Sopko L; Masakova L; Roziakova L; Martinka J; Batorova A
Bratisl Lek Listy; 2016; 117(7):388-96. PubMed ID: 27546540
[TBL] [Abstract][Full Text] [Related]
11. Endothelial microparticles delivering microRNA-155 into T lymphocytes are involved in the initiation of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Zhang R; Wang X; Hong M; Luo T; Zhao M; Shen H; Fang J; Li X; Zang S; Chen P; Nie D; Zheng P; Wu Q; Xia L
Oncotarget; 2017 Apr; 8(14):23360-23375. PubMed ID: 28423578
[TBL] [Abstract][Full Text] [Related]
12. Macrophage migratory inhibitory factor (MIF) expression in acute graft-versus-host disease (GVHD) in allogeneic hemopoietic stem cell transplant recipients.
Lo JW; Leung AY; Huang XR; Lie AK; Metz C; Bucala R; Liang R; Lan HY
Bone Marrow Transplant; 2002 Sep; 30(6):375-80. PubMed ID: 12235522
[TBL] [Abstract][Full Text] [Related]
13. [Gut microbiota and graft-versus-host disease: broad-spectrum antibiotic use increases post-allogeneic hematopoietic stem cell transplant graft-versus-host disease-related mortality].
Shono Y
Rinsho Ketsueki; 2017; 58(7):835-842. PubMed ID: 28781282
[TBL] [Abstract][Full Text] [Related]
14. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings.
Leung AY; Kwok J; Lie AK; Chen P; Chen FE; Liang R
Haematologica; 2001 Jun; 86(6):652-6. PubMed ID: 11418376
[TBL] [Abstract][Full Text] [Related]
15. Acute graft versus host disease in hematopoietic stem cell alotransplant recipients.
Krstevska S; Genadieva-Stavric S; Pivkova A; Stojanovski Z; Georgievski B; Balkanov T
Med Arh; 2011; 65(5):260-4. PubMed ID: 22073847
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
18. Effect of Graft-versus-Host Disease Prophylaxis Regimens on T and B Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation.
Törlén J; Gaballa A; Remberger M; Mörk LM; Sundberg B; Mattsson J; Uhlin M
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1260-1268. PubMed ID: 30710687
[TBL] [Abstract][Full Text] [Related]
19. Alpha/beta T-cell depleted grafts as an immunological booster to treat graft failure after hematopoietic stem cell transplantation with HLA-matched related and unrelated donors.
Rådestad E; Wikell H; Engström M; Watz E; Sundberg B; Thunberg S; Uzunel M; Mattsson J; Uhlin M
J Immunol Res; 2014; 2014():578741. PubMed ID: 25371909
[TBL] [Abstract][Full Text] [Related]
20. Acute graft-vs-host disease: pathobiology and management.
Goker H; Haznedaroglu IC; Chao NJ
Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
